Compound Screening TRIZ Cases

Norlimbanol isomers inhibit trimethylamine activation, resolving insufficient masking of strong fishy odors in personal care applications.

Forskolin-induced swelling of intestinal organoids measures cystic fibrosis transmembrane conductance regulator function.

Engineered cells employ synergistic activation mediator CRISPR-Cas9 to enhance cytochrome P450 expression, resolving in vitro toxicity assay inaccuracies.

SspB adaptor mediates tunable protein degradation rates using modified ssrA tags, resolving constitutive expression constraints without genomic disruption.

Measuring MT1-MMP-cleaved EphA2 fragments resolves the lack of reliable molecular markers by identifying specific cancer progression stages.

RANKL-binding molecules mediate stem cell maturation to increase cartilage matrix production without inducing calcification.

Measuring serum sVCAM concentrations provides sensitive alpha-4 integrin inhibition data without requiring fresh blood samples.

MyD88/ERK inhibitors block protein interactions to potentiate chemotherapy agents, overcoming DNA repair resistance in cancer cells.

Antigen binding proteins target HLA-peptide complexes to resolve insufficient specificity in cancer treatment.

A semaphorin 3A-derived peptide induces mast cell apoptosis to treat allergic skin conditions.

Cell-based assay screens compounds stabilizing Parkin protein to restore proteasome function, addressing therapeutic agent identification bottlenecks.

GCP-II metalloproteinase degrades beta-amyloid monomers and insoluble aggregates, overcoming the limited substrate scope of neprilysin.

Pre-filled reagent containers in a single-use cartridge eliminate manual handling errors and reduce preparation time during coagulation testing.

Co-culture assay detects indolent cell conversion to predict recurrence and drug resistance.

A biosensor detects RAF kinase dimerization using bioluminescence resonance energy transfer.

A recombinant mycobacteriophage delivers fluorescent reporter genes to detect Mycobacterium tuberculosis infection within twelve hours.

D8 and D10 metal complexes bind amyloid fibrils to trigger supramolecular self-assembly and red-shifted fluorescence emission.

Modified host cells express odorant receptors to identify compounds that bind or suppress malodorous substances.

Targeting the MUC1-FADD-MUC1 complex disrupts apoptosis resistance in cancer cells, offering new therapeutic strategies.

Measuring TRPV4, lysophosphatidylcholine, and miRNA-146a levels diagnoses cholestatic itch to enable effective treatment despite unclear pathophysiology.

A fusion protein comprising RNase L and split luciferase fragments enables real-time measurement of 2-5A levels in live cells.

Engineered mono-PARPs use orthogonal NAD+ analogues to identify isoform-specific targets, bypassing time-consuming deletion assays.

Compounds induce FoxM1 alternative splicing toward inactive variants, suppressing cancer cell proliferation.

A screening method detects schizophrenia onset by measuring functional levels of protein 14-3-3ζ in biological samples.

Cow antibody scaffold polypeptides present cyclic peptides to overcome peptide stability limits and enable targeting of previously undruggable disease targets.

Segmenting aptamer libraries recovers information content from limited sample volumes.

USP47 inhibitors block deubiquitinating enzyme activity to trigger targeted cancer cell death.

A computer system identifies surrogate markers in secondary tissues to monitor gene activity patterns.

Engineered hepatocytes create in situ liver cancer models that mimic spontaneous tumorigenesis while eliminating time-consuming genetic crosses.

Rapafucin libraries use extraction and intermediary principles to resolve ligand activity interference during simultaneous human proteome screening.

Selective CXCR3B antagonists prevent melanocyte destruction without suppressing immune function, addressing vitiligo treatment limitations.

Linker-FRET oligonucleotides detect molecular interactions using short probes.

A profluorescent nitroxide probe detects lipid peroxidation inhibition via fluorescence emission.

Antisense nucleic acids reduce PC4 expression to improve tumor specificity while lowering toxicity to normal cells.

Multimerizing fusion proteins generate fluorescent foci that resolve positional and temporal data lost in conventional assays.

AI algorithms screen genomic libraries to identify repurposed compounds, collapsing discovery time and cost from decades to days.

Detecting compound binding to the DRP1 protein GTPase domain enables early cytotoxicity assessment.

Optimized FRET assays measure fluorescence lifetime changes to identify modulators of the SERCA-phospholamban complex in membrane environments.

A yeast screening system identifies therapeutic compounds that inhibit homocysteine-induced amyloid-like fibril formation.

Solidifying a liquid matrix secures skin biopsies on porous membranes, preserving 3D structure during fragile road or air transport.

SWAP-70 inhibitor screening targets upstream regulatory mechanisms to prevent IgE synthesis, avoiding antibody-triggered allergic reactions.

FKBP52-Tau interaction screening identifies drug candidates modulating protein binding to treat neurological disorders involving Tau dysfunction.

A recombinant cell system transduces protein-protein interactions into gene expression using histidine kinase variants.

A 3D printer produces magnified physical models of hair surfaces from imaging data.

A caveolin-1 scaffolding domain peptide inhibits collagen expression by binding to PKC and ERK signaling molecules.